Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
Typically, there are two paths biotechs take when going public — seeking VC funding or raising capital via a reverse merger. However, INmune Bio chose a third path.
Much like in many other areas of the drug development continuum, the focus now in the cold chain is on data and how it can be unlocked and analyzed in real time to save money, time, and resources — while also better ensuring patient safety.
As the industry’s appetite for creating and using data-driven insights to improve clinical outcomes continues to grow, so does the need to integrate and validate disparate data sources. Efforts to impose greater consistency and rigor should be welcomed by all.
Life science leaders must balance their need to apply AI technologies to improve patient care, and bottom lines — without getting caught-up in the AI hype machine.
Let’s face it … pitching potential investors is a remarkable opportunity. It could be your one shot at getting your idea or company off the ground, so you better be appealing, tantalizing, and even provocative.
Women who are starting life sciences companies often do not have access to a network of mentors and advisors, whose strong advocacy establishes instant credibility and opens the doors to investors.
Here are some examples of why “soft skills,” such as those related to relationship building, leadership, and communication, are essential to today’s pharma and biotech leaders.
Companies frequently talk about being patient-centric. But what I don’t hear discussed as often is the role of the patient after a drug is approved. And I am convinced it is equally important. Why? Because patients are not static; they grow and change over time.
Aside from the clinical opportunity that gene therapy products present; they do introduce tremendous complexity into both the manufacturing and commercial processes. Remember these three points before developing your gene therapy plan.
While the costs and reputational implications associated with pharma data breaches are enough to pay heed to cybersecurity, these compromises can pose a serious threat to patient safety.
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
Mark Rothera spent the majority of his career working for U.S.-based biopharmas. So, when he had the opportunity to work in his home country and preferred therapeutic area, he pursued it relentlessly.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
Rob Wright provides insight into the categories and shared attributes of superbosses, as derived from 10 years of research and more than 200 interviews by Sydney Finkelstein, #23 on the Thinker50 2017 rankings.
Rob Wright discusses the difference between collaboration and teamwork, and what companies and leaders should be focusing on.